{"status": "Ok", "redirect_url": "https://www.prnewswire.com//news-releases/kodiak-sciences-completes-enrollment-in-first-pivotal-cohort-in-the-phase-3-peak-trial-of-ksi-101-for-macular-edema-secondary-to-inflammation-and-reaffirms-topline-clinical-data-release-remains-on-track-for-december-2026-302844806.html", "message": "News view counter 867925 successfully enlarged"}